Lung Cancer
US Focus Meeting 2026
📍 Sheraton Grand Nashville Downtown, 623 Union St, Nashville, TN 37219
🗓️ May 1-2, 2026
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the Lung Cancer Focus Meeting 2026, to be held at on May 1 - 2, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Lung Cancer research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of Lung Cancer US Focus Meeting 2026:
Charu Aggarwal, MD, MPH, FASCO
She, her, hers
University of Pennsylvania, Philadelphia, PA
Stephen Liu, MD
Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
olivia.wright@md-education.com
Agenda & Faculty
May 1, 2026 | Day 1
Session I: Advanced EGFR Mutant NSCLC
Moderated by:
TBD
KOL TBD
TBD
09:05 PM
Competing First-Line Strategies: MARIPOSA and FLAURA2
Xiuning Le, MD
MD Anderson Cancer Center, Houston, TX
09:25 PM
Ivonescimab and Other Second Line Options
Liza Villaruz, MD
UPMC Hillman Cancer Center, Pittsburgh, PA
09:45 PM
Evolving Role of ADCs for EGFR+ NSCLC
Zosia Piotrowska, MD
Massachusetts General Hospital, Boston, MA
Session II: Targeted Therapy in the Early Stage Setting
Moderated by:
TBD
TBD
TBD
10:45 AM
(Neo)adjuvant: Current, Future, Biomarkers
Brian Henick,, MD
Columbia University Irving Medical Center, New York, NY
11:05 AM
Consolidation Post Chemoradiation
Narjust Florez, MD
Dana-Farber Cancer Institute, Boston, MA
11:25 AM
MRD and ctDNA
Christian Rolfo, MD
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Session III: Early-stage immunotherapy
Moderated by:
TBD
TBD
TBD
1:40 PM
Neoadjuvant and Perioperative Standards
Tina Cascone, MD
MD Anderson Cancer Center, Houston, TX
2:00 PM
Future Directions for Perioperative Care
Ryan Gentzler, MD
University of Virginia, School of Medicine, Charlottesville, VA
2:20 PM
Novel Strategies in Unresectable NSCLC
Balazs Halmos, MD
Albert Einstein College of Medicine, Bronx, NY
Session IV: Small Cell Lung Cancer (ES/LS)
Moderated by:
TBD
TBD
TBD
4:05 PM
Current Standards for First Line and Maintenance
Alissa Cooper, MD
Dana-Farber Cancer Institute, Boston, MA
4:25 PM
Integrating T-Cell Engagers for SCLC
Hossein Borghaei, MD
Fox Chase Cancer Center, Temple Health, Philadelphia, PA
4:45 PM
Defining the Role for ADCs and Bispecifics
Misty Shields, MD
Indiana University School of Medicine, Indianapolis, IN
Agenda & Faculty
May 2, 2026 | Day 2
Session V: Mutations and Overexpression
Moderated by:
TBD
KOL TBD
TBD
9:05 AM
KRAS G12C - Current, Future
Melissa Johnson, MD
Sarah Cannon Research Institute, Nashville, TN
9:25 AM
HER2: ADC vs TKI
Mark Kris, MD
Memorial Sloan Kettering Cancer Center, New York, NY
9:45 AM
BRAF & MET
Ticiana Leal, MD
Emory Winship Cancer Institute, Atlanta, GA
Session VI: Immunotherapy in Advanced NSCLC
Moderated by:
TBD
TBD
TBD
10:45 AM
Current Standards
Justin Gainor, MD
Massachusetts General Hospital, Boston, MA
11:05 AM
Bispecifics and ADCs
Jonathan Riess, MD
UC Davis Comprehensive Cancer Center, Sacramento, CA
11:25 AM
Biomarker Development
Marina Garassino, MD
The University of Chicago Medicine, IL
Session VII: Fusions
Moderated by:
TBD
TBD
TBD
1:40 PM
ALK
Shirish Gadgeel, MD
Henry Ford Health, Detroit, MI
2:00 PM
ROS1
Jessica Lin, MD
Massachusetts General Hospital, Boston, MA
2:20 PM
RET, NTRK, NRG1
Christine M. Lovly, MD, PhD, FASCO
City of Hope, Duarte, CA
Session VIII: Other Thoracic Tumors
Moderated by:
TBD
TBD
TBD
4:05 PM
Mesothelioma
Melina Marmarelis, MD
Penn Medicine, Philadelphia, PA
4:25 PM
Thymic Malignancies
Chul Kim, MD
Georgetown University, Washington, DC
4:45 PM
Pulmonary Neuroendocrine
Lyudmila Bazhenova, MD
UC San Diego Health, CA
Charlotte Pilling
Project Manager
How long has Charlotte Pilling been in the business?
Charlotte Pilling has been with MD Education since 2024.
About Charlotte Pilling
As Assistant Project Manager at our Wigan office, I draw on my extensive background in customer-facing roles to ensure smooth communication and successful project delivery. With over 14 years of experience in customer service, I've built a strong foundation in client relations, problem-solving, and team coordination. My attention to detail, proactive approach, and passion for excellence are qualities I bring to every project, and I'm dedicated to supporting project teams.
